Shen Chun Fang, Rodenbrock Anja, Lanthier Stephane, Burney Elodie, Loignon Martin
Human Health Therapeutics Research Centre, National Research Council of Canada, Montreal, QC H4P 2R2, Canada.
Vaccines (Basel). 2024 May 10;12(5):524. doi: 10.3390/vaccines12050524.
Adenoviruses are efficient and safe vectors for delivering target antigens and adenovirus-based vaccines have been used against a wide variety of pathogens, including tuberculosis and COVID-19. Cost-effective and scalable biomanufacturing processes are critical for the commercialization of adenovirus-vectored vaccines. Adenoviral vectors are commonly produced through the infection of batch cultures at low cell density cultures, mostly because infections at high cell densities result in reduced cell-specific virus productivity and does not improve volumetric productivity. In this study, we have investigated the feasibility of improving the volumetric productivity by infecting fed-batch cultures at high cell densities. Four commercial and one in-house developed serum-free media were first tested for supporting growth of HEK 293 cells and production of adenovirus type 5 (Ad5) in batch culture. Two best media were then selected for development of fed-batch culture to improve cell growth and virus productivity. A maximum viable cell density up to 16 × 10 cells/mL was achieved in shake flask fed-batch cultures using the selected media and commercial or in-house developed feeds. The volumetric virus productivity was improved by up to six folds, reaching 3.0 × 10 total viral particles/mL in the fed-batch culture cultivated with the media and feeds developed in house and infected at a cell density of 5 × 10 cells/mL. Additional rounds of optimization of media and feed were required to maintain the improved titer when the fed-batch culture was scaled up in a bench scale (3 L) bioreactor. Overall, the results suggested that fed-batch culture is a simple and feasible process to significantly improve the volumetric productivity of Ad5 through optimization and balance of nutrients in culture media and feeds.
腺病毒是递送靶抗原的高效且安全的载体,基于腺病毒的疫苗已被用于对抗多种病原体,包括结核病和新冠病毒。具有成本效益且可扩展的生物制造工艺对于腺病毒载体疫苗的商业化至关重要。腺病毒载体通常通过在低细胞密度培养物中感染分批培养物来生产,主要是因为在高细胞密度下感染会导致细胞特异性病毒生产力降低,并且不会提高体积生产力。在本研究中,我们研究了通过在高细胞密度下感染补料分批培养物来提高体积生产力的可行性。首先测试了四种市售和一种内部开发的无血清培养基,以支持HEK 293细胞的生长和在分批培养中生产5型腺病毒(Ad5)。然后选择两种最佳培养基来开发补料分批培养物,以改善细胞生长和病毒生产力。使用选定的培养基和市售或内部开发的补料,在摇瓶补料分批培养物中实现了高达16×10个细胞/mL的最大活细胞密度。体积病毒生产力提高了多达六倍,在用内部开发的培养基和补料培养并在细胞密度为5×10个细胞/mL时感染的补料分批培养物中达到3.0×10个总病毒颗粒/mL。当补料分批培养物在实验室规模(3 L)生物反应器中放大时,需要进一步优化培养基和补料以维持提高的滴度。总体而言,结果表明补料分批培养是一种简单可行的方法,通过优化和平衡培养基和补料中的营养成分,可以显著提高Ad5的体积生产力。